Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 6, 2011

Receptos and Lilly Enter Agreement Focused on a GPCR Target

  • Receptos and Eli Lilly agreed to research and develop orally delivered small molecule modulators of an undisclosed GPCR target. They will advance the candidates into preclinical development based on shared structure-based drug design efforts that employ Receptos’s technology for determining GPCR crystal structure.

    Receptos’ approach to GPCR drug discovery combines traditional screening information with biophysical ligand screening using pure and stable receptor protein, chemistry structure-activity relationships, novel biological insight into allosteric binding sites, site specific mutagenesis to probe residue-ligand interactions, GPCR crystal structure, and co-crystal structure iterations.

    “The lead-generation focus of the collaboration aligns with our company’s strategic plan to contribute to the development of therapeutically relevant candidates for high-value targets, while maintaining freedom to conduct our own drug development, either with partners or on an independent basis,” says Faheem Hasnain, president and CEO of Receptos.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »